FMW Stock Overview
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Veru Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.46 |
| Beta | -0.45 |
| 1 Month Change | -16.01% |
| 3 Month Change | -30.61% |
| 1 Year Change | -19.29% |
| 3 Year Change | -89.97% |
| 5 Year Change | -84.86% |
| Change since IPO | -76.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| FMW | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -13.1% | -0.3% | -0.9% |
| 1Y | -19.3% | -13.3% | 13.5% |
Return vs Industry: FMW underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: FMW underperformed the German Market which returned 17.2% over the past year.
Price Volatility
| FMW volatility | |
|---|---|
| FMW Average Weekly Movement | 20.7% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: FMW's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: FMW's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 210 | Mitch Steiner | verupharma.com |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.
Veru Inc. Fundamentals Summary
| FMW fundamental statistics | |
|---|---|
| Market cap | €69.68m |
| Earnings (TTM) | -€30.33m |
| Revenue (TTM) | €16.04m |
4.3x
P/S Ratio-2.3x
P/E RatioIs FMW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMW income statement (TTM) | |
|---|---|
| Revenue | US$16.89m |
| Cost of Revenue | US$11.03m |
| Gross Profit | US$5.85m |
| Other Expenses | US$37.80m |
| Earnings | -US$31.94m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 34.67% |
| Net Profit Margin | -189.17% |
| Debt/Equity Ratio | 0% |
How did FMW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/04 04:24 |
| End of Day Share Price | 2025/03/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veru Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Yi Chen | H.C. Wainwright & Co. |